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AbstrAct
Introduction One in five patients with sepsis deteriorates 
within 48 hours after hospital admission. Regrettably, a 
clear tool for the early detection of deterioration is still 
lacking. The SepsiVit study aims to determine whether 
continuous heart rate variability (HRV) measurement can 
provide an early warning for deterioration in patients 
presenting with suspected infection or sepsis to the 
emergency department (ED).
Methods and analysis The protocol of a prospective 
observational study in the ED. We will include 171 adult 
medical patients presenting with suspected infection or 
sepsis and at least two systemic inflammatory response 
syndrome criteria. Patients with known pregnancy, 
cardiac transplantation or not admitted to our hospital are 
excluded. High sample frequency ECG signals (500 Hz), 
respiratory rate, blood pressure and peripheral oxygen 
saturation will be recorded continuously during the 
first 48 hours of hospitalisation using a bedside patient 
monitor (Philips IntelliVue MP70). Primary endpoint is 
patient deterioration, defined as the development of organ 
dysfunction, unplanned intensive care unit admission or 
in-hospital mortality. The ECG data will be used for offline 
HRV analysis. We will compare the HRV between two groups 
(deterioration/no deterioration) and analyse whether HRV 
provides an early warning for deterioration. Furthermore, we 
will create a multivariate predictive model for deterioration 
based on heart rate, respiratory rate and HRV. As planned 
secondary analyses, we (1) perform a subgroup analysis for 
patients with pneumosepsis and urosepsis and (2) determine 
whether HRV using lower sample frequencies (1 Hz or less) 
suffices to predict deterioration.
Ethics and dissemination The Institutional Review 
Board of the University Medical Center Groningen granted 
a waiver for the study (METc 2015/164). Results will 
be disseminated through international peer-reviewed 
publications and conference presentations. A lay  
summary of the results will be provided to the study  
participants.
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Protocol
strengths and limitations of this study
 ► With a sample size of 171 patients, the SepsiVit 
study is the largest prospective observational study 
in the emergency department (ED) to determine 
whether continuous heart rate variability (HRV) 
measurement may provide an early warning signal 
for patient deterioration in patients presenting to the 
ED with suspected infection or sepsis.
 ► Data are acquired using a commonly available 
bedside patient monitor at a high sample rate 
(500 Hz) and include besides the ECG signal, also 
respiratory rate, blood pressure and peripheral 
oxygen saturation.
 ► The data are continuously acquired during the first 
48 hours of hospitalisation.
 ► We plan a secondary analysis, to determine whether 
HRV using a lower sample frequency signals (1 Hz 
or less) suffice to predict patient deterioration; 
the lower sample frequency may enable the use 
of wearable devices for patient monitoring in the 
future.
 ► The SepsiVit study is performed in a single 
tertiary care teaching hospital, which may limit 
generalisability; however, the study may provide 
insights for further evaluation of HRV as warning 
signal for deterioration.
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IntroductIon
Despite the adoption of Surviving Sepsis Campaign (SSC) 
guidelines, early goal-directed therapy and decades 
of fundamental, translational and clinical research, 
sepsis-related morbidity and mortality remain unaccept-
ably high.1 2 Previous studies have shown that one in five 
patients presenting to the emergency department (ED) 
with infection or sepsis, deteriorate; most frequently 
within 48 hours after hospital admission.3 4 It remains 
unclear how early signs of patient deterioration and the 
response to treatment can be monitored in sepsis.2 5 The 
most recent SSC guidelines suggest that a thorough re-eval-
uation of available physiological variables, including 
routinely measured vital signs, may describe the patient’s 
clinical state and the response to treatment.2 
Traditionally, the diagnosis and monitoring of sepsis are 
based on infrequently measured discrete absolute values 
of vital signs, non-specific symptoms and scoring systems. 
In clinical practice, the crossing of certain thresholds of 
these vital signs are used to confirm the diagnosis and 
to monitor the response to treatment. These thresholds 
are derived from epidemiological research. However, 
because of the heterogeneous patient population and the 
unpredictability of an individual’s response to treatment, 
thresholds for the ‘average’ patient may not apply to or 
be beneficial for individual patients.6
Although vital signs of patients are continuously 
measured in the ED or intensive care unit (ICU), most 
of the measured data are discarded by only using discrete 
absolute values.6 7 Monitoring changes in vital signs over 
time, called variability analysis, provides an additional 
dimension to the data being measured and may provide 
information about response to treatment or early signs of 
patient deterioration.7 8
Like many other biological systems, the host response 
to infection is a complex non-linear system. Complex 
non-linear systems are composed of a virtually infinite 
number of interconnected variables, which are constantly 
changing. Complex systems have emergent properties 
that none of the individual parts have and that disappear 
on decomposition of the system into smaller parts. Small 
perturbations of individual variables in the system may be 
magnified or dampened depending on the state of the 
system, which may cause unpredictably large changes. 
The properties of a complex system help explain why 
chaotic dynamics may lead to unexpected rapid dete-
rioration or clinical improvement without identifiable 
cause.6 Changes of individual variables over time are 
called variability. Despite large degrees of variability of 
individual variables, the system as a whole will naturally 
settle in a remarkably small number of stable states. By 
using continuous variability analysis over time, it is theo-
retically possible to track the ‘state of the system’ over 
time. Furthermore, variability analysis could be used to 
determine prognosis and response to treatment of indi-
vidual patients contrary to traditional epidemiological 
thresholds.7 Therefore, continuous variability analysis 
has the potential to determine whether an individual 
patient is progressing towards a state of health or towards 
deterioration.
Many types of vital signs can be analysed using vari-
ability analysis, however, heart rate variability (HRV) is 
the most studied. HRV can be measured readily, easily, 
non-invasively and the most accurately.9 Although a 
couple of studies have been performed on HRV in adults 
with sepsis, variability analysis is most studied and success-
fully applied in neonates.6 The leading bedside clinical 
application of HRV has been studied in neonates by 
Moorman et al10. They created a composite measurement 
of HRV that predicts an increased likelihood of deterio-
ration in the subsequent 24 hours.6 In the adult popula-
tion, HRV has mostly been studied in small pilot studies 
and studies in ICU patients with sepsis and septic shock.6 
Reduced HRV has been associated with the diagnosis 
of sepsis, impending shock and patient deterioration.6 
In a small study, Barnaby et al, found a HRV threshold 
discriminating between deterioration and no deteriora-
tion.11 A study by Pontet et al in ICU patients suggests that 
a reduced HRV at ICU admission may be useful in iden-
tifying septic patients at risk for multiple organ failure.12 
The question remains whether a reduction in HRV is also 
present in patients presenting to the ED with infection 
or sepsis, since these patients appear to be generally less 
severely ill than ICU patients, and whether reduced HRV 
can be used as an early warning signal for impending 
patient deterioration in the ED population.
objectives
The primary objective of the SepsiVit study is to deter-
mine whether continuous HRV measurement in patients 
presenting to the ED with suspected infection or sepsis 
during their first 48 hours of hospitalisation can provide 
an early warning signal for patient deterioration. Further-
more, we plan a secondary analysis, to determine whether 
variability analysis of the heart rate using a lower sample 
frequency (1 Hz or less) would also be sufficient to predict 
patient deterioration.
MEthods And AnAlysIs
study design and setting
The SepsiVit study is a prospective observational study. 
The study will be conducted in the ED of the University 
Medical Center Groningen in the Netherlands, a tertiary 
care teaching hospital with over 34 000 ED visits annually.
The SepsiVit study is part of the research line on sepsis 
and infection in our department. One of the goals of 
this research line is to create a model for patient dete-
rioration and response to treatment in ED patients with 
suspected infection or sepsis. To create this model, we 
study various predictive variables, like clinical scoring 
systems, biomarker levels and vital signs.8 13 We have 
a special interest in patients with infection and sepsis 
without organ failure, since many of these patients deteri-
orate and they may benefit the most from early interven-
tion.3 4 14
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Table 1 Measured vital parameters and sample 
frequencies
Waveforms Sample frequency*
ECG (using EASI lead placement)
  Lead I 500 Hz
  Lead II 500 Hz
  Lead V 500 Hz
Respiratory waveform 125 Hz
Plethysmogram waveform 125 Hz
Numeric values
  ECG heart rate 1 Hz
  Respiratory rate (ECG impedance) 1 Hz
  Peripheral oxygen saturation 1 Hz
  Peripheral flow index 1 Hz
  Plethysmogram pulse rate 1 Hz
  Non-invasive blood pressure Every 4 hours
*The samples are recorded at the maximum frequency supported 
by the Philips Data Export Protocol for the Philips Intellivue MP70 
patient monitor.21
study population
Consecutive medical patients visiting the ED with fever 
and/or suspected infection or sepsis, will be screened 
for eligibility to be included in the study. The inclusion 
criteria are: (1) age of 18 years or older, (2) suspected 
infection or suspected sepsis, (3) two or more systemic 
inflammatory response syndrome criteria as defined by 
the International Sepsis Definitions Conference and (4) 
able to provide written informed consent.15 Patients are 
excluded from the study in case of: (1) known pregnancy, 
(2) when the patient is not admitted to the hospital from 
the ED or is transferred to a location outside our hospital 
(eg, another hospital, nursing home, long-term care 
facility, etc) or (3) the patient had a cardiac transplanta-
tion. Patients with a cardiac transplantation are excluded 
since it is known that they have a highly reduced HRV.16
The original design and ethics approval for this study 
originate from before the introduction of the Sepsis-3 
definitions; therefore, the inclusion criteria are based on 
the Sepsis-2 definitions.15 17 We chose not to adjust the 
inclusion criteria to the Sepsis-3 definitions, since patients 
meeting the Sepsis-3 criteria have signs of organ failure by 
definition.17 However, in terms of the new Sepsis-3 defi-
nitions, we are especially interested in the patients who 
present in the ED with infection and deteriorate to sepsis 
within 48 hours after hospital admission. This group of 
patients has the highest potential to benefit from early 
intervention when (early) signs of organ failure are 
detected.
Endpoint and definitions
The primary endpoint for this study is patient deterio-
ration. We define patient deterioration as the develop-
ment of organ dysfunction, unplanned ICU admission 
or in-hospital mortality. For organ dysfunction, we distin-
guish between acute kidney injury (AKI), liver failure 
and respiratory failure, as defined below. For AKI, the 
Kidney Disease Improving Global Outcomes guideline 
criteria will be used.18 Liver failure is defined as total bili-
rubin level >34.2 µmol/L (2.0 mg/dL) and either alka-
line phosphatase or a transaminase level greater than 
two times normal.19 Respiratory failure is defined as the 
need for mechanical ventilation or either hypoxaemia 
(PaO2 <8.0 kPa) or hypercapnia (PaCO2 >6.5 kPa) in the 
arterial blood gas analysis or a peripheral oxygen satura-
tion <90% when breathing ambient air or <95% with at 
least 2 L/min of oxygen supplementation.20 Unplanned 
ICU admission was defined as a transfer to the ICU of 
a patient from a general ward during the patient’s stay 
in the hospital for any reason. In-hospital mortality is 
defined as all-cause mortality during the patient’s stay in 
the hospital.
data collection
Eligible patients visiting our ED between 8:00 and 23:00 
will be recruited for the study by a trained member of 
our research staff. After consent from the patient, high 
sample rate vital signs will be recorded (table 1). The 
data collected by the research staff, furthermore, include 
sociodemographic information, patient history, treat-
ment parameters, results from routine blood analysis 
and follow-up during the patient’s stay in the hospital. 
The patient’s electronic medical records will be used 
as a source for patient characteristics and for patient 
follow-up.
The high sample rate vital signs (table 1) of participants 
in the study are measured using a mobile bedside patient 
monitor (Philips IntelliVue MP70 System with MultiMea-
surement Module; Philips, Eindhoven, The Netherlands) 
during the first 48 hours of hospitalisation. Patients trans-
ferred from the ED to the nursing wards are normally 
not continuously monitored on the wards; therefore, the 
mobile patient monitor is transferred with the patient to 
the ward. All alarms on the mobile patient monitor are 
deactivated and the option to set any alarms has been 
disabled. The deactivated alarms minimise the poten-
tial influence of the monitoring on the care process on 
the wards. Furthermore, sounding alarms may worry the 
patient. The data on the screen of the monitor are avail-
able to the ward staff, as this was an essential requirement 
for their cooperation.
Patients transferred to the ICU are continuously moni-
tored using the stationary bedside monitors in the ICU 
(of the same model as the mobile bedside monitor). 
Since these monitors are essential for patient monitoring 
and care in the ICU, no changes are made to the moni-
tor’s settings; alarms can be configured or enabled at the 
discretion of the ICU staff. Although high sample rate 
vital signs are routinely measured in the ICU, most of 
the data are not stored and thus discarded.6 Therefore, 
both on the wards and on the ICU, the patient monitor is 
connected to a laptop containing custom-made software 
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to record and store this data. The software uses the Philips 
IntelliVue Data Export Interface Protocol to record the 
vital sign data of the patient monitor with the highest 
supported sample frequency (table 1) and it stores the 
raw data into a database.21 The raw data in this database 
will be used as a source for the offline analysis of HRV.
data analysis plan
The raw ECG data stored in the database needs to be 
preprocessed before it can be used for the offline anal-
ysis of HRV. Preprocessing consist of several steps. First, 
baseline wander, power line and movement artefacts as 
well as other noise will be filtered out of the raw signal. 
Second, non-sinus rhythm ectopic beats will be detected 
and corrected for using an interpolation algorithm, since 
these beats cause an artificially high HRV.22 Third, the 
R-peaks will be detected in the resulting signal. The result 
of the preprocessing are the time periods between two 
successive R-peaks, that is, the R-R intervals.
After preprocessing, the R-R interval data will be 
used for HRV analysis in the time domain and in the 
frequency domain (the technical terms of HRV analysis 
are explained in online supplementary material 1).7 16 
The time domain consists of a statistical evaluation of the 
R-R interval data. A reduced HRV measured in the time 
domain has been associated with poor prognosis and/or 
increased mortality for other diseases (described above).7 
We will calculate the SD of N-N intervals (online supple-
mentary material 1) for the time domain, which reflects 
the variability caused by all cyclic components in the 
period of the recording.16
The frequency domain will be analysed by determining 
the power in predefined frequency bands: high frequency 
(HF, 0.15–0.4 Hz), low frequency (LF, 0.04–0.15 Hz) and 
very low frequency (0.003–0.04 Hz) band. The power in 
the HF band is mainly influenced by vagal activity. The 
LF band indicates sympathetic activity, although some 
studies suggest that vagal activity plays a role as well.22 23
The preprocessing of the raw data and the analysis of 
the HRV will be performed by an automated algorithm 
implemented in MATLAB (The MathWorks, Natick, 
Massachusetts, USA), to prevent a subjective bias in the 
HRV analysis. The algorithm will be developed and the 
HRV analysis will be performed by a member of our 
research staff who is blinded to the clinical outcomes 
of the patients. Before analysing our own data using the 
algorithm, the algorithm’s accuracy will be tested using 
the MIT-BIH arrhythmia database.24 The MIT-BIH data-
base contains 48 ECG recordings including annotations 
of R-peaks, noise and ectopic beats and can therefore be 
used to validate our algorithm.
We will compare the HRV measurements between two 
groups (deterioration/no deterioration) using a t-test 
after logarithmic transformation of the data, since the 
data will likely have a χ² distribution. We will perform a 
windowed, time-locked to onset of deterioration, logistic 
regression analysis to look at which moment in time there 
is a significant difference in HRV between the groups, 
that is, an early warning of patient deterioration. Further-
more, we will create an initial predictive model for dete-
rioration based on heart rate and respiratory rate, using 
multivariate logistic regression. By forward variable selec-
tion, we will extend this model with the HRV measure-
ments to analyse whether these measurements improve 
the predictive accuracy of the model. The regression 
model is considered a hypothesis-generating analysis 
to analyse the added value of HRV over traditionally 
recorded vital signs for a future larger follow-up study.
The focus of sepsis may have an influence on the HRV 
measurements. Therefore, we plan a secondary analysis 
in which we will perform a subgroup analysis for patients 
with pneumosepsis and urosepsis for the HRV measure-
ments mentioned above.
To determine whether heart rate measurements 
with a sample rate of 1 Hz or less also discriminate the 
two groups (deterioration/no deterioration), we plan 
another secondary analysis depending on the discrimi-
nating power found by the primary analysis. These lower 
sample rates would enable the use of wearable or low-cost 
devices to monitor patient deterioration and would 
dramatically reduce the amount of data that need to be 
stored, processed and analysed.
HRV is mostly and preferably measured under 
controlled circumstances.16 However, we measure HRV 
in patients who are potentially mobile in various hospital 
environments (ED, ICU and nursing wards). To deter-
mine the possible effects of interference or artefacts and 
the quality of our measurements, we plan an interim anal-
ysis of the data after inclusion of the first 25 patients.
sample size
This study’s sample size was calculated using data from 
a pilot study in our department and information avail-
able in literature.8 In the pilot study, overall rate of 
patient deterioration during hospitalisation was 36%.8 
Studies using HRV to predict mortality, sepsis severity 
and impending septic shock have reported highly vari-
able effect sizes for the various HRV measurements.12 25–29 
Since these measurements all provide their own distinct 
information, it is difficult to designate one of them as the 
most important and to base the estimated effect size on 
that measurement.7 The majority of effect sizes (Cohen’s 
d) reported are well over d=0.6, therefore, we chose this 
value as a conservative estimate for effect size. We chose 
a conservative estimate to prevent overestimation of the 
expected difference between the deterioration/no dete-
rioration groups. Using the information described above, 
we calculated the required sample size for the study using 
G*Power: Statistical Power Analyses for Windows.30 The 
power calculation resulted in a minimum sample size of 
114 patients (table 2).
To ensure sufficient power of the study results, we 
performed a number of corrections on the calculated 
sample size. First, we estimated that 20% of the patients 
who participate in the study may drop out of the study 
for various reasons, for example, early discharge, patient 
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Table 2 Calculation of the study’s required sample size
Sample size calculation
Test: two-tailed t-test difference between two 
independent groups
  Power 80%
  α 0.05
  Estimated effect size d 0.6
  Estimate group allocation ratio N2/N1
  (36% deterioration)
0.36
  Calculated sample size 114
Corrections
  Estimated loss to follow-up +20%
  Estimated dysrhythmia +10%
  Subgroup analysis for pneumosepsis and 
urosepsis
  (70% of patients)
+30%
  Required sample size 171
discomfort (continuous measurement), development 
of delirium and so on. Second, it is important that HRV 
calculations are performed on subsequent beats of a sinu-
soidal rhythm, as ectopic beats and arrhythmic events 
affect the outcomes of these calculations.16 Therefore, we 
corrected for patients with dysrhythmia. The incidence of 
dysrhythmias in patients with sepsis is approximately: 8% 
in patients with sepsis, 10% in severe sepsis and 23% in 
septic shock patients.19 The ratio between sepsis, severe 
sepsis and septic shock in our department is approx-
imately 6:3:1 based on data from our pilot study and 
another study in our department.8 13 We calculated, using 
a weighted average and this ratio that approximately 10% 
of the patients in our population will have dysrhythmia. 
Third, we corrected for the planned secondary anal-
ysis in the subgroups with pneumosepsis and urosepsis. 
Together, these two sources of sepsis account for approx-
imately 70% of all patients presenting with sepsis to our 
ED. Therefore, we corrected the sample size with 30% 
to account for other sources of sepsis. After these three 
corrections, the required sample size for the study is 171 
patients (table 2).
duration and current status of the study
The study was prospectively registered in The Netherlands 
National Trial Register on 4 January 2017 under number 
NTR6168. Recruitment of patients is ongoing and the 
first patient was included on 16 January 2017. At the time 
of writing (June 2017), 34 patients have been included in 
the study. It is expected that the required sample size of 
171 patients will be reached by the first quarter of 2018.
EthIcs And dIssEMInAtIon
Ethical aspects and informed consent
This study will be carried out in accordance to the Decla-
ration of Helsinki, the Dutch Agreement on Medical 
Treatment Act and the Dutch Personal Data Protection 
Act. The Institutional Review Board of the University 
Medical Center Groningen ruled that the Dutch Medical 
Research Involving Human Subjects Act is not applicable 
for this study and granted a waiver.
Eligible patients visiting the ED will be asked to partic-
ipate in the study by a member of our research staff. 
On agreement to participate, the patient will be asked 
to provide written informed consent. Participants are 
informed that they can withdraw their informed consent 
at any moment without the need to provide a reason. 
In case a participant withdraws informed consent, data 
collection will be ended immediately and the data will be 
discarded. Participants are also informed that they can 
end their participation in the study at any moment, for 
example, when the patient experiences too much discom-
fort from the monitor cables or ECG electrodes. However, 
in the latter case, the data collected until that point will 
be used in the final analysis.
Additional risks for patients caused by participation in 
the study are negligible. All participants will receive stan-
dard care according to the hospital’s protocols and the 
attending physician’s discretion. Participation in the study 
does not involve any alterations in treatment protocol.8
Protocol compliance
The study will be performed in accordance to the study 
protocol reviewed by the Institutional Review Board. Any 
changes to the protocol first need approval from the 
Review Board before they can be put into practice, except 
if following the original protocol presents an immediate 
risk to the patient. Any deviations from the protocol will 
be recorded and when required reported to the Institu-
tional Review Board.
dissemination
On conclusion of the study, the results will be dissemi-
nated via international peer-reviewed journals and confer-
ences. We plan to disseminate the results of the planned 
secondary analysis with lower sample rate (<1 Hz) vital 
signs in a separate manuscript. However, we will ensure 
that the manuscript will contain the proper cross-refer-
ences and preferably submit it to the same journal. A 
lay summary of the results will be provided to the study 
participants.
PotEntIAl IMPAct And futurE PlAns
The SepsiVit study will be, to the best of our knowledge, 
the largest study of its kind that prospectively records 
high sample frequency vital signs with the objective to 
develop an early warning signal for patient deterioration 
using HRV in patients presenting with suspected infec-
tion or sepsis to the ED. Furthermore, it is the first study 
that continuously records high sample frequency ECG 
signals for 48 hours and also other vital signs like respira-
tory rate, oxygen saturation and plethysmogram (table 1). 
Although our primary focus lies on the variability analysis 
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using the ECG signal, the recorded data of the other 
vital signs may be used to optimise the model for patient 
deterioration. The study has, therefore, the potential to 
discover a new tool for patient deterioration in this ED 
patient population.
The bedside patient monitors used in clinical prac-
tice today, require lots of wires between the monitor and 
the patient’s body. These monitors, therefore, restrict 
patients in their movements and mobility. The cables 
and electrodes may, furthermore, cause discomfort to the 
patient. Therefore, we plan to investigate the use of wear-
able devices for the monitoring of patients in the future. 
Wearable devices may improve the ease of measurement 
and patient comfort.
If the results of the SepsiVit study can reliably differ-
entiate between patients who deteriorate and those 
who do not deteriorate based on HRV and provide 
early warning of deterioration, we plan to implement 
continuous measurement of ECG signals with (near) 
real-time analysis of HRV in our ED. This early warning 
system using continuous variability analysis can poten-
tially be used to monitor response to treatment in 
sepsis and to guide treatment. Furthermore, we plan to 
develop a self-learning computer-guided early warning 
model for patient deterioration by integrating various 
variability measures and biomarker values using 
machine learning technology. This model may provide 
a tool to improve care for and outcomes of patients 
with infection and sepsis in the ED.
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